SynthesisJournal of molecular medicine (Berlin, Germany)2025
The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: a systematic review.
Synthesis in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thyroid-Originating Extracellular Vesicles Harbor Thyroid-Specific Biomarkers with Potential Relevance for Thyroid Cancer Recurrence Detection.International journal of molecular sciences · 2026Article
- Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto's thyroiditis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The incidence of thyroid cancer, the most common endocrine malignancy, has increased by 313% in the past four decades and is now the seventh most common cancer worldwide. There is an urgent need for non-invasive diagnostic, prognostic, and surveillance biomarkers to improve patient outcomes. Given the promising role of extracellular vesicles (EVs) as liquid biopsy biomarkers, a systematic review of the literature was conducted to evaluate their diagnostic and prognostic utility in thyroid cancer. We also assessed the quality of included studies giving special emphasis to methodology, reporting standards, and adherence to MISEV2018 guidelines. A comprehensive search was conducted across Web of Science, Ovid Medline, Ovid Embase, Scopus, and Emcare for English-language studies published from inception to March 2025. Search terms included a combination of relevant keywords and subject Headings. A total of 40 studies met the inclusion criteria. Most focused on papillary thyroid carcinoma, with relatively a minority investigating follicular thyroid carcinoma. The majority examined small EVs (exosomes), with microRNAs (miRNAs) being the most studied EV biomarkers, followed by proteins, circular RNAs, long non-coding RNAs, mRNAs, DNA, procoagulant phospholipids, and biophysical characteristics. No studies investigated EV lipids or metabolites as potential thyroid cancer biomarkers. This systematic review highlights the strong potential of EVs as diagnostic and prognostic biomarkers in thyroid cancer. However, larger prospective patient cohorts are needed to validate current findings. Clinical translation will require standardised methodologies and robust comprehensive reporting aligned with MISEV2018 guidelines, enhancing reproducibility and paving the way for multicentre clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.